Quintiles expands Phase I capabilities
Quintiles opens new unit for patients and healthy volunteers in London, UK.
Biopharma firm Quintiles has expanded its research facility in London, increasing its Phase I capacity and extending its ability to drive progress in translational medicine.
With capacity for 35 patients and healthy volunteers, the extension brings the total number of Phase I beds in London to 105 and globally to 385. This is expected to increase later this year with the opening of a Phase I unit in Hyderabad, India, initially with 50 beds, and with capacity for double this.
"With our expanded facility in London and our planned facility in Hyderabad we will be better able to provide an integrated Phase I research solution that facilitates robust decisionmaking early," said Eddie Caffrey, senior vice president, Global Phase I at Quintiles.
Electronic data capture and automated workflow systems link Quintiles Phase I facilities around the world, to provide harmonised data and reporting across multiple sites.
Located at Guy's Hospital in London, the research facility is adjacent to one of only five Biomedical Research Centres (BRCs) in the UK. Quintiles will work closely with experts from the BRC to drive forward the translation of science onto hospital wards.